Exenatide synthetic | Radio Compass News | PharmaCompass.com

Grow Your Pharma Business Digitally

X

Market Place

Sourcing support

Sourcing Support

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

All News Exenatide Synthetic

AstraZeneca`s Byetta Receives Approval in US

01 Nov 2024 //

FDA

From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes

09 Oct 2019 //

PHARMACEUTICAL TECHNOLOGY

Eli Lilly picks up an oral GLP-1 diabetes drug from Roche sub for $50M

27 Sep 2018 //

ENDPTS

ADA: Trulicity bests Victoza, Bydureon in real-world study

25 Jun 2018 //

FIERCE PHARMA

AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval

03 Apr 2018 //

DRUGDELIVERY

Novo gets FDA blessing for Type 2 diabetes drug Ozempic

06 Dec 2017 //

FIERCE PHARMA

AZ GLP-1 trailer Bydureon gets a facelift with BCise approval

23 Oct 2017 //

FIERCE PHARMA

AstraZeneca receives US FDA approval for once-weekly Bydureon BCise injectable

23 Oct 2017 //

PHARMABIZ

Why did AstraZeneca`s Bydureon fail to cut CV risks?

14 Sep 2017 //

FIERCE PHARMA

AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon

31 May 2017 //

FIERCE PHARMA

AstraZeneca asthma shot hits goal but diabetes drug lags rival

23 May 2017 //

REUTERS

AZ Taps 3SBio to Help Drive Sales of Diabetes Meds Byetta, Bydureon in China

14 Oct 2016 //

FIERCE PHARMA

AstraZeneca, Teva settle Byetta patent suit; generics on their way

25 Jun 2016 //

FIERCE PHARMA

Novo Nordisk`s weekly diabetes drug goes 5-for-5 in Phase III

24 Feb 2016 //

FIERCE BIOTECH

Once-a-week diabetes meds are similar in safety and effectiveness

07 Dec 2015 //

REUTERS

Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD

16 Sep 2015 //

PR NEWS WIRE

AZ`s Bydureon tops doc-payments list with $22B

08 Jul 2015 //

FIERCE PHARMA